Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease

被引：27
作者：
Carman N. [1 ,2 ]
Mack D.R. [1 ,2 ]
Benchimol E.I. [1 ,2 ,3 ]
机构：
[1] CHEO Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, K1H 8L1, ON
[2] Department of Pediatrics, University of Ottawa, Ottawa, ON
[3] School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON
来源：
Current Gastroenterology Reports | 2018年 / 20卷 / 5期
关键词：
Azathioprine; Biologics; Inflammatory bowel disease; Pediatrics; Therapeutic drug monitoring; Treatment;
D O I：
10.1007/s11894-018-0623-z
中图分类号：
学科分类号：
摘要：
Purpose of review: Therapeutic drug monitoring (TDM) has emerged as a useful tool to optimize the use of drug therapies in adults with inflammatory bowel disease (IBD), including both Crohn’s disease (CD) and ulcerative colitis (UC), especially during the use of biological therapies, for which the pharmacokinetics and pharmacodynamics are highly variable among patients. Fewer data exist in children. This review examines the current literature on TDM in pediatric IBD. Recent findings: Drug clearance is affected by a number of patient and disease factors. For thiopurines, adjusting dosing by monitoring 6-thioguanine (6TGN) and 6-methylmercaptopurine ((6MMP) levels is demonstrated to maximize response and minimize toxicity, while monitoring metabolite levels when treating with anti-tumor necrosis factor (anti-TNF) remain controversial. While in adults the use of TDM in the setting of loss of response to anti-TNF therapy is established, in children, only a small number of studies exist, but these too have encouraging results. There are however, conflicting data regarding the optimal timing of TDM, comparing “reactive” monitoring and “proactive” monitoring. No such data exist in pediatrics. TDM is cost-effective, and dose reduction may represent a safety benefit. There are limited adult data for use of TDM for the newer biologics, vedolizumab and ustekinumab, but early results suggest similarly promising utility. Summary: The use of TDM in pediatric IBD is increasing in clinical practice, with similar efficacy to adults demonstrated in children with loss of response to anti-TNF therapy. More prospective studies are needed in children to examine proactive monitoring and utility of TDM with newer biologics. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 120 条
[1]  
Benchimol E.I., Manuel D.G., Guttmann A., Nguyen G.C., Mojaverian N., Quach P., Mack D.R., Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends, Inflamm Bowel Dis, 20, 10, pp. 1761-1769, (2014)
[2]  
Benchimol E.I., Mack D.R., Nguyen G.C., Snapper S.B., Li W., Mojaverian N., Quach P., Muise A.M., Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease, Gastroenterology, 147, 4, pp. 803-814, (2014)
[3]  
Benchimol E.I., Bernstein C.N., Bitton A., Carroll M.W., Singh H., Otley A.R., Vutcovici M., el-Matary W., Nguyen G.C., Griffiths A.M., Mack D.R., Jacobson K., Mojaverian N., Tanyingoh D., Cui Y., Nugent Z.J., Coulombe J., Targownik L.E., Jones J.L., Leddin D., Murthy S.K., Kaplan G.G., Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases, Am J Gastroenterol, 112, 7, pp. 112
[4]  
Bressler B., Marshall J.K., Bernstein C.N., Bitton A., Jones J., Leontiadis G.I., Et al., Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus, Gastroenterology, 148, 5, pp. 1035-1058, (2015)
[5]  
Feuerstein J.D., Nguyen G.C., Kupfer S.S., Falck-Ytter Y., Singh S., American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease, Gastroenterology, 153, 3, pp. 827-834, (2017)
[6]  
Osterman M.T., Mucosal healing in inflammatory bowel disease, J Clin Gastroenterol, 47, 3, pp. 212-221, (2013)
[7]  
Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R.H., Broussard D.L., Tang K.L., van der Woude C., Rutgeerts P., Infliximab, azathioprine, or combination therapy for Crohn’s disease, N Engl J Med, 362, 15, pp. 1383-1395, (2010)
[8]  
Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Et al., Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial, Gastroenterology, 132, 1, pp. 52-65, (2007)
[9]  
Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P., Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 106, 4, pp. 644-659, (2011)
[10]  
Hyams J., Damaraju L., Blank M., Johanns J., Guzzo C., Winter H.S., Et al., Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis, Clin Gastroenterol Hepatol, 10, 4, pp. 391-399, (2012)
12345678910